Draft NICE guidance rejects Yescarta

The National Institute for Health and Care Excellence (NICE) has issued draft guidance rejecting Yescarta (axicabtagene ciloleucel) for B-cell lymphoma, one of two leading CAR-T immunotherapies.

The European Medicines Agency (EMA) approved Marketing Authorisation for the drug at the end of June, but NICE’s draft guidance does not recommend the treatment.

The Guidance makes positive comments about the treatment’s apparent effectiveness, but questions its cost-effectiveness, citing cost estimates of over £50,000 per QALY.

In addition, NICE challenged a lack of study evidence comparing the treatment against salvage chemotherapy which, in the absence of a standardised treatment, is the most common existing approach.

NICE is currently consulting on the draft guidance.

Tagged with

Published 28. August 2018 in News, News EU, News UK